VT 3989
Alternative Names: VT-3989Latest Information Update: 25 Jun 2024
Price :
$50 *
At a glance
- Originator Vivace Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action TEA domain transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Malignant-mesothelioma; Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research
- 31 Dec 2023 VT 3989 is still in phase-I development in Malignant-mesothelioma in USA and Australia (PO, Capsule)
- 31 Dec 2023 VT 3989 is still in phase-I development in Solid-tumours (Late-stage disease, Metastatic disease) in USA and Australia (PO, Capsule)